The Single Market in Pharmaceuticals
Margaret K. Kyle ()
Additional contact information
Margaret K. Kyle: PSL Research University and CEPR
Review of Industrial Organization, 2019, vol. 55, issue 1, No 7, 135 pages
Abstract This paper examines the state of the single market in the European Union (EU) for pharmaceuticals. As with other products, the EU has adopted a number of institutions and policies to encourage integration and the free movement of goods. Over time, member states are more similar in the availability of pharmaceutical products, as well as in the patents that protect them. New pharmaceuticals are generally available sooner and in more EU members. However, there are large differences in the number and mix of products across member states. Because the pricing of pharmaceuticals remains a national competence, price variation also persists—though this may be desirable from a social welfare standpoint.
Keywords: European Union; Integration; Intellectual property; Parallel trade; Pharmaceuticals; Regulation (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://link.springer.com/10.1007/s11151-019-09694-6 Abstract (text/html)
Access to full text is restricted to subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:kap:revind:v:55:y:2019:i:1:d:10.1007_s11151-019-09694-6
Ordering information: This journal article can be ordered from
http://www.springer. ... on/journal/11151/PS2
Access Statistics for this article
Review of Industrial Organization is currently edited by L.J. White
More articles in Review of Industrial Organization from Springer, The Industrial Organization Society Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla ().